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Abstract:  Neuromuscular Diseases are a heterogeneous molecular, clinical and prognosis group. Progress has been 
achieved in the understanding and classification of these diseases. 
Cardiac involvement in neuromuscular diseases namely conduction disorders, ventricular dilatation and dilated cardiomy-
opathy with its impact on prognosis, is often dissociated from the peripheral myopathy. Therefore, close surveillance is 
mandatory in the affected patients. In this context, preventive therapy (beta-blockers and angiotensin converting enzyme 
inhibitors) has been recently recommended in the most common Neuromuscular Diseases, Duchenne Muscular Dystrophy 
and Myotonic Dystrophy.  
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INTRODUCTION 
During last years, progress has been achieved in the un-
derstanding and classification of neuromuscular diseases. 
Cardiac involvement (Table 1) in the neuromuscular dis-
eases namely conduction disorders, ventricular dilatation and 
dilated cardiomyopathy with its impact on prognosis, is often 
dissociated from the peripheral myopathy. Therefore, close 
surveillance is mandatory in affected patients. In this con-
text, preventive therapy has been recently recommended in 
the most common forms the Duchenne Muscular Dystrophy 
and the Myotonic Dystrophy. 
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DMD: Duchenne muscular dystrophy; BMD: Becker muscular dystrophy; 
LGMD: Limb girdle muscular dystrophy; EDMD: Emery dreifuss muscular 
dystrophy; +: Low risk; ++: moderate risk; +++: High risk. 
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Duchenne (DMD) and Becker (BMD) Muscular Dystro-
phy 
In the DMD, prognosis depends on the ventilatory assis-
tance (respiratory muscle dysfunction is the main reason for 
death, survival thus depend on the ventilatory support). In 
BMD, prognosis rather depends on the existence of a car-
diomyopathy. 
Both diseases are X-linked recessive disorders due to the 
Dystrophine gene abnormality with almost absence of Dys-
trophine in DMD and reduced Dystrophine in BMD [1-2]. 
Epidemiology and Clinical Presentation (Table 2) 
DMD is the most common inherited neuromuscular dis-
order with an incidence of 30/100000 live male births. A 
cardiomyopathy is always present but is masked by severe 
muscle weakness. The electrocardiogram (ECG) is often 
abnormal. Death occurs by the age of 20 years old in DMD 
versus 40-50 years old in BMD [3]. 
Cardiac Management (Table 3) 
Angiotensin Converting Enzyme Inhibitors (ACEI) have 
been shown to be effective in preventing left ventricular 
(LV) remodeling in ischemic cardiomyopathy and reducing 
LV hypertrophy and fibrosis which contribute to ventricular 
arrhythmias and sudden cardiac death (SCD) [4]. Recently, 
ACEI have been studied in patients with muscular dystro-
phies. Early initiation of treatment with perindopril was as-
sociated with lower mortality in patients with DMD with 
normal LV ejection fraction at study entry [5]. Likewise, 
others [6] found that a beta-blocker (BB), in addition to 
ACEI improves LV systolic function in patients with muscu-
lar dystrophy. 
In the light of these positive results, many authors [5-6] 
recommend initiation of ACEI and/or BB early after diagno-
sis of the muscular dystrophy especially in DMD. 94    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Bouhouch et al. 
Some studies suggested that corticosteroids might have a 
beneficial effect in DMD [7]. 
Males with DMD must be followed-up more closely than 
female with DMD or those with BMD [7].  
Myotonic Dystrophies 
The most common form is Myotonic Dystrophy 1(MD1) 
also known as the Steinert disease with an incidence of 
1/8000 births [1-10]. 
It is an autosomal dominant disorder due to mutational 
expansion of a repetitive trinucleotide sequence (CTG) in the 
3'-untranslated region of the DMPK (myotonic dystrophy 
protein kinase gene) on chromosome 19q13.3. SCD is the 
major risk in affected patients and may occur at a very young 
age. [8-9] 
Epidemiology and Clinical Presentation (Table 4) 
MD1 is the most common form of MD in adults between 
20 and 25 years old [1-10]. 
The mean age survival is 53 years old. Cardiovascular 
Events (LV dysfunction, ischemic heart disease, pulmonary 
emboli or SCD) represents 30% of all cause mortality [10]. 
Moreover, cardiac involvement may be the first expres-
sion of the disease [10]. 
Conduction Disorders 
First degree AV bloc is seen in up to 40% cases. Bundle 
branch blocs, a long QT, ST-T modifications and axis devia-
tions are other possible findings [10-11]. 
Because progression of these conduction disorders is un-
predictable, in addition to the high prevalence of infra-His 
defects (conduction impairment below the His bundle), an 
electrophysiology study (EPS) should always be performed. 
Late potentials (LP), rather than a risk indicator for ven-
tricular arrhythmias, seems to correlate with a delayed acti-
vation along the His-Purkinje system [10-12]. LP can thus be 
used for selection of candidates for an EPS (Table 5). 
Table 2. Epidemiology and Clinical Presentation of DMD and BMD 
 BMD    DMD  
Incidence  3/100.000 live male births  30/100.000 live male births 
Cardiac involvement  CMP** 50%  CMP* 25% after 6 y/o 
ECG / Holter ECG  Abnormal 75% 
Abnormal 90%  
Sinus tachycardia 26% 
Progression*** More  benign(survival   40-50 y/o)  Rapid (symptoms > 5 y/o, death ~ 20 y/o) 
* Masked by the severity of the peripheral myopathy. 
** The right ventricular may be the first to be involved. 
*** MRI (Magnetic Resonance Imaging) could be used to monitor disease progression and possibly response to therapy. 
CMP, Cardiomyopathy; y/o, years old. 
 
Table 3. Cardiac Management of DMD and BMD 
 
 BMD    DMD  
Corticosteroids Unknown  May be beneficial 
ACEI  9 y/o 
Diuretics, BB and anti-arrhythmics if CHF 
Unknown  Would be beneficial 
Follow-up 
, ECG+TTE every 5 years 
asymptomatic, ECG+TTE after 16 y/o 
, ECG+TTE every 2 years10 y/o then once a year 
asymptomatic, ECG+TTE every 5 years after 16 
y/o 
ACEI, Angiotensin converting enzyme inhibitors; BB, BetaBlockers; CHF, Congestive heart failure; TTE, TransThoracic echocardiography. 
Table 4. Epidemiology and Clinical Presentation of Myotonic Dystrophies 
 
  MD2 or PROMM  MD1 Steinert 
Genetic alterations  Repetitive CCTG Chr 3    Autosomal dominant repetitive CTG Chr 19q13.3 
Neurological disorder  Proximal  Distal 
SCD Risk  Less common & late  Common and early 
PROMM, PROxymal myotonic myopathy; SCD, Sudden cardiac death. Management of Cardiac Involvement in NeuroMuscular Diseases  The Open Cardiovascular Medicine Journal, 2008, Volume 2    95 
Asymptomatic sinus bradycardia has been reported in 
pediatric series [13]. 
Tachycardia 
- Supraventricular tachycardias are very common with up 
to 25% patients presenting atrial fibrillation or and/or atrial 
flutter [10-12]. 
- Ventricular tachycardias (VT) are frequent, thus any 
symptomatic patient should undergo an EPS (Table 5). 50% 
of patients who had a pace-maker (PM) for AV bloc, develop 
VT and are at risk of SCD. Different mechanisms are de-
scribed for the VT, a particular one is the bundle branch re-
rentry (BBR) VT since it can be cured by radiofrequency 
ablation [10,12,14]. 
Cardiomyopathy and other Disorders 
Patients present symptoms of heart failure in only 1.8% 
cases because they are usually limited in their daily activity. 
In fact, cardiac imaging can unmask 14% of asymptomatic 
LV dysfunction [10-12]. 
Cardiac Management [10,12,13] 
While waiting for several ongoing studies that will 
evaluate arrhythmias and cardiac manifestations of DM1, 
suggestions for management of cardiovascular complications 
in DM1 patients are as follows: 
An ECG every 6 to 12 months is advised in asympto-
matic patients with a normal baseline ECG. 
EPS is indicated as previously mentioned in Table 5.  
According to recent guidelines [15], PM implantation is a 
class1 indication in the presence of a third degree and ad-
vanced second degree AV block at any anatomic level with 
or without symptoms. If a VT at EPS is only a BBRVT, ra-
diofrequency ablation of 1 BB (usually the right BB) is 
probably curative and the patient may not need an implant-
able cardioverter defibrillator (ICD) if he/she does not meet 
the classical criteria for ICD placement and if there is no 
other inducible VT with a mechanism other than BBR. 
Echocardiography is recommended in symptomatic pa-
tients and in those patients with conduction disturbances or 
arrhythmia. 
Emery-Dreifuss Dystrophies (EDMD) 
Epidemiology and Clinical Presentation 
Two forms are described; EDMD2 is the autosomal 
dominant type caused by mutations of the LMNA gene at 
1q21 (which encodes lamins A and C); EDMD1 is the X-
linked form caused by mutations of the STA gene at Xq28 
(which encodes the nuclear membrane protein emerin) [1-2]. 
ECG is abnormal by age 20 to 30 years old with sino-
atrial or auriculo-ventricular conduction disorders, atrial ar-
rhythmias, ventricular arrhythmias (particularly in EDMD2) 
[13]. Cardiomyopathy (CMP) represents 2% of CMP in chil-
dren and may develop earlier in the EDMD2 [13].  
Survival is 35% at the age of 45 years old with a high 
risk of SCD [1-2-11]. 
Cardiac Management 
Family members of the EDMD, especially EDMD2, must 
be screened after the age of 10 years old, even in the absence 
of symptoms [13].  
It is advised to perform during follow-up, an ECG, a Hol-
ter ECG and an Echocardiography once a year. An exercise 
test may be helpful in children and an EPS will be indicated 
as for the MD1. 
Anticoagulation therapy must be started in the setting of 
atrial arrhythmia or atrial standstill [13]. An ICD is indicated 
in the EDMD2 associated with dilated cardiomyopathy espe-
cially in the adulthood [1-13]. 
Table 5. Indications for EPS in DM1 Patients 
 
Family History 
Sudden death, Ventricular Fibrillation/Sustained VT, Pacemaker or car-
dioverter defibrillator implant 
Symptoms  Palpitations, Syncope, Dizziness 
Conduction disorders at ECG/HolterECG/Signal averaged ECG 
First degree AV block 
Second or third degree AV block 
QRS > 120 ms 
LBBB, RBBB+LAFB 
Positive late potentials 
Sinus node dysfunction 
Sinus pause > 3 seconds 





Frequent ventricular premature beats 
Non-sustained or Sustained VT 
AV, atrioventricular; AF, atrial fibrillation; A FLT, atrial flutter; LAFH, left anterior fascicular hemiblock; LBBB, left bundle branch block; RBBB, right 
bundle branch block; VT, ventricular tachycardia. 96    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Bouhouch et al. 
Limb-girdle Muscular Dystrophies (LGMD) 
Several of these disorders are associated with clinically 
significant cardiac involvements [1,2,11,13]. 
LGMD Type 1B 
In this autosomal dominant form, conduction disorders 
progression resembles EDMD2 that can be relevant of a PM 
or an ICD [1-13]. 
Other LGMD  
Type 2C, 2D, 2E, 2F LGMD 
They are sarcoglycanopathies due to defects on gamma, 
alpha, beta and delta sarcoglycans. 
Cardiomyopathy is possible except in alpha-sarcogly-
canopathy. 
Fanin reported cardiomyopathy in 10 patients with 
LGMD type 2E from 6 different families [11]; atrial fibrilla-
tion was found in 2 out of these 10 patients.  
Though guidelines are lacking in these dystrophies, it is 
advised to repeat ECG/Holter and echocardiography every 2 
to 5 years. Empirical therapy by ACEI and /or BB is used in 
the setting of LV dysfunction [13]. 
Type 21 LGMD,  is an alpha-sarcoglycanopathy that as-
sociates a dilated cardiomyopathy in 50% cases [13]. 
Calpainopathies(LGMD 2A) and Dysferlinopathies,  
have a Becker phenotype except for the cardiac involvement 
[13]. 
The  Facioscapulohumeral  Muscular Dystrophies 
(FSHMD) 
Described by Landouzy and Dejerine, it is an autosomal 
dominant disease due to a deletion on the 4q35 chromosome. 
Arrhythmias are rare in this muscular dystrophy [1-11]. 
Mitochondrial Myopathies 
It is a heterogeneous group due to mutations in mito-
chondrial DNA. Two phenotypes are described: [1,11,13] 
1. The Kearns-Sayre syndrome oculo-pharyngal myopa-
thy, with chronic progressive external ophtalmoplegia. Infra-
His conduction disorders are progressive [1-11]. Therefore, 
an EPS is performed in symptomatic patients and in presence 
of ECG abnormalities. Cardiac pacing improves survival of 
patients with a prolonged infra-His conduction interval at the 
EPS. Patients with ventricular arrhythmias may require an 
ICD[13-15]. 
2. The Melas syndrome and Leber disease, may associate 
a supraventricular tachycardia due to an accessory pathway 
[1-11]. 
CONCLUSIONS 
Advances in the understanding of the incidence, the type, 
the pathophysiology and molecular biology of the various 
peripheral myopathies and their cardiac complications had 
allowed recommendations for the cardiological follow-up of 
the patients especially in the commonest diseases (Steinert's 
disease, Duchenne and Becker muscular dystrophies and 
EDMD). Little is known regarding the management of car-
diac complications in children with the same diseases; pro-
spective studies in this age group of patients are therefore 
mandatory. This may lead to early screening in affected 
families and adjustment of guidelines for device implantation 
in adults for this young population.  
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